Related Experiment Video
Updated: May 28, 2026
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
[Epitheliotropic lymphomas: better identification for improved treatment].
1Dermatologie, APHP, Hôpital Saint Louis, Université Paris 7, Unité Inserm U976, Centre de Recherche sur la Peau, 1 Avenue Claude Vellefaux, 75010 Paris. martine.bagot@sls.aphp.fr
Bulletin De L'Academie Nationale De Medecine
|November 3, 2011
Summary
Mycosis fungoides and other cutaneous T-cell lymphomas are common skin cancers. Cutaneous B-cell lymphomas vary in aggressiveness, requiring tailored treatments to avoid overtreatment of indolent forms.
Area of Science:
- Dermatology
- Oncology
- Hematology
Background:
- Mycosis fungoides is the most common cutaneous T-cell lymphoma (CTCL).
- Other CTCLs include folliculotropic mycosis fungoides, pagetoid reticulosis, granulomatous slack skin, and Sézary syndrome.
- B-cell lymphomas constitute 25% of cutaneous lymphomas.
Purpose of the Study:
- To review the classification and clinical characteristics of cutaneous lymphomas.
- To highlight the varying prognoses and treatment considerations for different subtypes.
- To emphasize the importance of personalized treatment strategies.
Main Methods:
- Review of existing literature on cutaneous T-cell and B-cell lymphomas.
- Classification based on cell lineage (T-cell vs. B-cell).
- Correlation of specific subtypes with clinical presentation, location, and disease course.
Main Results:
- Cutaneous T-cell lymphomas (CTCLs) encompass mycosis fungoides and related conditions.
- Sézary syndrome presents with erythroderma, lymphadenopathy, and a more aggressive course.
- Primary cutaneous B-cell lymphomas include indolent follicle center cell and marginal zone types, and aggressive diffuse large B-cell lymphomas (leg type) and intravascular large B-cell lymphomas.
Conclusions:
- Cutaneous lymphomas exhibit diverse clinical behaviors, ranging from indolent to aggressive.
- Accurate diagnosis and subtyping are crucial for appropriate management.
- Treatment should be individualized to the specific lymphoma subtype and patient, avoiding overly aggressive approaches for indolent forms.
